Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.53 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.53 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 5/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726204 | 0.90 | CSNK1D (0.51) | CSNK1DMAPK14CSNK1A1CDK4GSK3B | |
| SCHEMBL5726162 | 0.89 | CSNK1D (0.51) | CSNK1DMAPK14CSNK1A1CDK4GSK3B | |
| SCHEMBL5726207 | 0.87 | CSNK1D (0.50) | CSNK1DMAPK14CDK4GSK3BMAPK8 | |
| SCHEMBL5875531 | 0.87 | MAPK14 (0.54) | CSNK1DMAPK14CSNK1A1CDK4GSK3B | |
| SCHEMBL6486071 | 0.86 | CSNK1D (0.49) | CSNK1DMAPK14CSNK1A1CDK4GSK3B | |
| SCHEMBL6487282 | 0.86 | CSNK1D (0.49) | CSNK1DMAPK14CSNK1A1CDK4GSK3B | |
| SCHEMBL6486093 | 0.85 | CSNK1D (0.48) | CSNK1DMAPK14CSNK1A1CDK4GSK3B | |
| SCHEMBL5385928 | 0.85 | MAPK14 (0.54) | CSNK1DMAPK14CSNK1A1CDK4GSK3B | |
| SCHEMBL5725033 | 0.84 | MAPK8 (0.47) | CSNK1DMAPK14CDK4MAPK8MAPK9 | |
| SCHEMBL5875496 | 0.84 | CSNK1D (0.45) | CSNK1DMAPK14CSNK1A1CDK4GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | CSNK1D 2789/4885MAPK14 1551/4885CSNK1A1 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.